OrthoSpin News
9 articles
Trendlines Announces Acquisition of Portfolio Company OrthoSpin Ltd.
The Trendlines Group Ltd. has announced the 100% acquisition of its portfolio company, OrthoSpin Ltd., by Synthes GMBH for a total of US$79.5 million in cash. The acquisition will have a material positive impact on the net tangible assets per share and earnings per share of Trendlines. OrthoSpins automated strut system offers a new solution to the external circular fixation market used in bone lengthening and correcting limb deformities. OrthoSpin received FDA clearance for its latest device in January 2021 and has completed initial clinical cases in the U.S. and Israel. The acquisition was led by Synthes GMBH, part of DePuy Synthes, the Orthopaedics company of Johnson & Johnson.
Acquisition
OrthoSpin Ltd. Receives FDA Regulatory Clearance for its G2 System
OrthoSpin Ltd. has received regulatory clearance from the FDA for its second generation robotic system for orthopedic treatments. The system automates external fixation orthopedic treatments, addressing patient compliance challenges and providing real-time feedback for physician follow-up. The Generation 2 system is more user-friendly, covers all strut range sizes, and is lighter by 20%. The company has completed initial clinical cases in the US and Israel with the FDA-cleared Generation 1 system. OrthoSpin believes that robotic automation will revolutionize the hexapod bone deformity market. The system is approved in Israel and cleared for use in the USA. OrthoSpin is a portfolio company of The Trendlines Group Ltd.
CustomersPartners
Israeli robotic orthopedic co OrthoSpin raises $5m
OrthoSpin, an Israeli robotic orthopedic device developer, has completed initial clinical cases with its FDA-cleared OrthoSpin Generation 1 system. The company has also raised $5 million in a Series B financing round led by The Trendlines Group and Johnson & Johnson Innovation - JJDC, Inc. OrthoSpin is developing a robotic, digitally enabled external fixation system for orthopedic treatments. The funding will enable the company to accelerate the development of its Gen 2 system and move into clinical use later this year.
Investment
OrthoSpin Ltd. Raises up to US$5 Million in Series B Financing
OrthoSpin Ltd. has raised US$5 million in a series B financing for its robotic, digitally enabled external fixation system for orthopedic treatments. The investment round was led by Johnson & Johnson Innovation – JJDC, Inc. The company has completed initial clinical cases with its FDA-cleared OrthoSpin Generation 1 system, which makes pre-programmed adjustments automatically without patient involvement. The funding will accelerate the development of OrthoSpins Gen 2 system and move it into clinical use later this year.
Investment
OrthoSpin Ltd. Raises up to US$5 Million in Series B Financing
OrthoSpin has raised US$5 million in a series B financing round led by Johnson & Johnson Innovation – JJDC, Inc. The company has developed a robotic, digitally enabled external fixation system for orthopedic treatments. The system eliminates the need for manual adjustment by patients and provides real-time feedback for physicians. OrthoSpin has completed initial clinical cases with its FDA-cleared OrthoSpin Generation 1 system and plans to move into clinical use with the Gen 2 system later this year. The investment will support the development of the Gen 2 system and bring OrthoSpins system to market.
Investment
OrthoSpin Receives FDA Regulatory Clearance
OrthoSpin Ltd., a portfolio company of The Trendlines Group Ltd., has received regulatory clearance from the FDA for its smart, robotic external fixation system for orthopedic treatments. The system addresses the challenges of patient compliance and lack of real-time feedback for physicians. It automatically makes pre-programmed adjustments, eliminating the need for manual adjustments and patient training. The system also allows for monitoring of biomechanical parameters and real-time updates to physicians. OrthoSpin completed an investment round led by Johnson & Johnson Innovation - JJDC, Inc. in 2018.
CustomersPartners
OrthoSpin Ltd. Completes $3 Million Raise for Orthopedic Robotic External Fixation System
OrthoSpin Ltd. has completed an investment round of $3 million for its smart, robotic external fixation system for orthopedic treatments. The investment was led by Johnson & Johnson Innovation - JJDC, Inc. The OrthoSpin system eliminates the need for patient involvement by making pre-programmed adjustments automatically and continuously. It also enables physicians to chart patient progress and adjust treatment programs when required. The funding will accelerate the development process and broaden clinical trials, bringing OrthoSpins system to market.
Investment
Let a robot tend your fixation device after leg surgery
Israeli startup OrthoSpin has developed a smart robotic external orthopedic fixation system that makes precise pre-programmed adjustments to promote proper positioning, growth, and healing. The system was successfully used on a 15-year-old patient in Jerusalem, resulting in a less painful process and reduced soft tissue damage. OrthoSpin presented a working prototype of the device at a conference and expects to secure funding from a major player in the industry to refine the prototype and continue with clinical trials. The company also plans to develop a companion physician interface app for monitoring patient progress remotely. Founded in 2014, OrthoSpin aims to introduce the first advance in the trauma market for external fixation in the past 20 years.
Customers
Successful First in Human for OrthoSpin's Robotic External Orthopedic Fixation System
OrthoSpin Ltd., a portfolio company of The Trendlines Group Ltd., has successfully completed a first-in-human case for its smart, robotic external fixation system for the treatment of an orthopedic deformity. The system automatically and continuously adjusts according to the prescribed treatment regimen, eliminating the need for patient involvement. The precise adjustments of OrthoSpins system result in a less painful process and are expected to reduce soft tissue damage. OrthoSpin plans to conduct additional trials and submit for regulatory clearance in 2018. The company aims to bring its product to market and improve orthopedic treatment outcomes.
Customers
